Friday, March 29, 2024
ADVT 
Health

Study hints, can't prove, survivor plasma fights COVID-19

Darpan News Desk The Canadian Press, 14 Aug, 2020 10:33 PM
  • Study hints, can't prove, survivor plasma fights COVID-19

Mayo Clinic researchers reported a strong hint that blood plasma from COVID-19 survivors helps other patients recover, but it’s not proof and some experts worry if, amid clamour for the treatment, they'll ever get a clear answer.

More than 64,000 patients in the U.S. have been given convalescent plasma, a century-old approach to fend off flu and measles before vaccines. It's a go-to tactic when new diseases come along, and history suggests it works against some, but not all, infections.

There’s no solid evidence yet that it fights the coronavirus and, if so, how best to use it. But preliminary data from 35,000 coronavirus patients treated with plasma offers what Mayo lead researcher Dr. Michael Joyner on Friday called “signals of efficacy.”

There were fewer deaths among people given plasma within three days of diagnosis, and also among those given plasma containing the highest levels of virus-fighting antibodies, Joyner and colleagues reported.

The problem: This wasn’t a formal study. The patients were treated in different ways in hospitals around the country as part of a Food and Drug Administration program designed to speed access to the experimental therapy. That so-called “expanded access” program tracks what happens to the recipients, but it cannot prove the plasma — and not other care they received — was the real reason for improvement.

Rigorous studies underway around the country are designed to get that proof, by comparing similar patients randomly assigned to get plasma or a dummy infusion in addition to regular care. But those studies have been difficult to finish as the virus waxes and wanes in different cities. Also, some patients have requested plasma rather than agreeing to a study that might give them a placebo instead.

“For 102 years we’ve been debating whether or not convalescent plasma works,” said Dr. Mila Ortigoza of New York University, referring to plasma’s use in the 1918 flu pandemic. This time around, “we really need undisputable evidence.”

Ortigoza is co-leading one such study, which this week is expanding to three other states — Connecticut, Florida and Texas. Her team also is working to pool data with several other clinical trials in other regions, in hopes of faster answers.

“There’s concern about when there will be a clear answer,” agreed infectious disease specialist Dr. Jeffrey Henderson of Washington University in St. Louis.

He’s hopeful the clinical trials will push forward but said the Mayo report is consistent with smaller, earlier plasma studies and "an example of making the best you can of the data that’s available."

When the body encounters a new germ, it makes proteins called antibodies that are specially targeted to fight that particular infection. The antibodies float in plasma — the yellowish, liquid part of blood. Because it takes a few weeks for antibodies to form, the hope is that transfusing someone else’s antibodies could help patients fight the virus before their own immune system kicks in.

The Mayo findings were posted online ahead of scientific peer review. They show that 20% of people given high-antibody plasma within three days of diagnosis had died within 30 days compared with 30% of people treated later with low-antibody plasma.

The FDA has been closely considering if the evidence is good enough to allow so-called emergency use of convalescent plasma, a step that would make it even harder for more rigorous testing to be completed. FDA didn’t immediately comment Friday.

Tens of thousands of COVID-19 survivors have donated their plasma, and blood banks have issued calls for even more to meet the demand as the coronavirus continues to ravage the U.S. According to AABB, the American Association of Blood Banks, a quarter of hospitals it checks weekly are reporting waits of more than 24 hours in obtaining requested plasma.

Beyond whether plasma generally helps, scientists want to know when it should be used — for the very sick or at the earliest sign of infection? And what’s the right dose? COVID-19 survivors harbour widely varying amounts of antibodies, which Ortigoza said is difficult to measure before the donated plasma is used. She said another question is which of the many types of antibodies are the best to use.

Joyner noted that the expanded access program wasn’t meant to replace rigorous studies but was originally designed to track 5,000 people and see if plasma was safe. Instead, the program skyrocketed.

“There’s probably reasonable, actionable evidence from our findings to really reaffirm” historic lessons of plasma therapy, that earlier use is better, he said.

MORE Health ARTICLES

CFIA investigates unsolicited seed shipments

CFIA investigates unsolicited seed shipments
The Canadian Food Inspection Agency is warning gardeners not to plant "unauthorized seeds" from packages they weren't expecting.

CFIA investigates unsolicited seed shipments

Scientists get closer to blood test for Alzheimer's disease

Scientists get closer to blood test for Alzheimer's disease
An experimental blood test was highly accurate at distinguishing people with Alzheimer’s disease from those without it in several studies, boosting hopes that there soon may be a simple way to help diagnose this most common form of dementia.

Scientists get closer to blood test for Alzheimer's disease

COVID-19 recovery can take a few weeks even for young adults

COVID-19 recovery can take a few weeks even for young adults
Recovering from even mild coronavirus infections can take at least two to three weeks, according to U.S. research published Friday.

COVID-19 recovery can take a few weeks even for young adults

WATCH: Your help needed, A Mother's Plea to Help Baby Aryan Fight SMA #donate #support

WATCH: Your help needed, A Mother's Plea to Help Baby Aryan Fight SMA #donate #support
DO WATCH & PLEASE SHARE AS MUCH AS POSSIBLE! Baby Aryan's parents urge the community to help as the baby was diagnosed with TYPE 1 SPINAL MUSCULAR ATROPHY (SMA). There is a treatment available called ZOLGENSMA which is the most expensive drug in the world at this time it costs 2.1 million dollars USD (2.8 Million CAD).

WATCH: Your help needed, A Mother's Plea to Help Baby Aryan Fight SMA #donate #support

FDA tells doctors to discuss overdose antidote with patients

FDA tells doctors to discuss overdose antidote with patients
Doctors who prescribe opioid painkillers should tell their patients about a potentially life-saving medication that can reverse drug overdoses, according to new federal guidelines issued Thursday.

FDA tells doctors to discuss overdose antidote with patients

Virus antibodies fade fast but not necessarily protection

Virus antibodies fade fast but not necessarily protection
New research suggests that antibodies the immune system makes to fight the new coronavirus may only last a few months in people with mild illness, but that doesn’t mean protection also is gone or that it won’t be possible to develop an effective vaccine.

Virus antibodies fade fast but not necessarily protection